News
VERA
39.95
+1.09%
0.43
Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk
Analysts say Vertex Pharmaceuticals did not engage with other major player in the kidney-disease treatment space. Vertex's deal for Alpine Therapeutics is for a treatment for a common kidney disease. The two companies are both developing treatments for the disease.
Dow Jones · 1d ago
Weekly Report: what happened at VERA last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at VERA last week (0408-0412)?
Weekly Report · 04/15 12:04
Validea Detailed Fundamental Analysis - VERA
NASDAQ · 04/12 20:08
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
NASDAQ · 04/12 16:36
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Vertex Pharmaceuticals Incorporated agreed to acquire Alpine Immune Sciences Inc for $65 per share or approximately $4.9 billion in cash. Evercore notes the deal as a surprise move for Vertex. The company has been criticized for its capital allocation in the past.
Benzinga · 04/11 18:47
Vertex Pharma upgraded at Evercore on Alpine Immune deal
Vertex Pharmaceuticals to buy immunotherapy developer Alpine Immune Sciences for $4.9B. Evercore ISI upgraded Vertex to Outperform from In-Line on Thursday. The company's lead drug, povetacicept, could be the fourth to enter the immunotherapy market.
Seeking Alpha · 04/11 12:36
Analysts’ Top Healthcare Picks: Emergent Biosolutions (EBS), Vera Therapeutics (VERA)
TipRanks · 04/11 11:20
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Rallybio (NASDAQ:RLYB) stock is rocketing more than 76% on news of a collaboration with Johnson & Johnson. The biggest pre-market stock movers this morning are acquisition deals, collaborations, earnings reports and more. A breakdown of the 10 biggest moving stocks on Thursday morning.
Investorplace · 04/11 11:19
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
TipRanks · 04/11 10:40
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation rose sharply in today's pre-market trading. The company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rent the Runway, Inc. Shares rose 40.8% to $10.42 after the company reported mixed fourth-quarter financial results.
Benzinga · 04/11 10:14
These Stocks Are Moving the Most Today: Alpine Immune, Regeneron, Costco, Constellation Brands, CarMax, and More
Alpine Immune Sciences was rising 36% to $64.15 after agreeing to be acquired by Vertex Pharmaceuticals. Justice Department accuses Regeneron Pharmaceuticals of fraudulent practices. Rent the Runway was rising 43% in premarket trading. Costco Wholesale raised its quarterly cash dividend by 14%.
Barron‘s · 04/11 08:31
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
Shares of Vera Therapeutics were up late Wednesday. Alpine Immune Sciences, whose lead candidate is similar to Vera's, said it would be acquired at a premium. Alpine agreed to be acquired by Vertex Pharmaceutical for about $4.9 billion in cash. Vera stock was up 9.9% to $45.74 in late trading.
Dow Jones · 04/10 22:33
FATE, ALPN and RLAY are among after hour movers
On the Move FATE, ALPN and RLAY are among after hour movers. Rallybio Corporation and Alpine Immune Sciences are among the biggest gainers. Performant Financial and NioCorp Developments are the biggest losers in the after hour.
Seeking Alpha · 04/10 21:20
12 Health Care Stocks Moving In Wednesday's After-Market Session
Rallybio shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by 10.52% during the session.
Benzinga · 04/10 20:31
Alpine Immune jumps on report of takeover interest
Alpine Immune Sciences (ALPN) jumps 13% on report of takeover interest. The biotech firm is working on a treatment for inflammatory kidney diseases. Vera Therapeutics (VERA) spiked up 11% in sympathy with Alpine Immune. The company has hired advisers to consider a possible deal.
Seeking Alpha · 04/10 16:41
VERA THERAPEUTICS INC <VERA.O>: JP MORGAN RAISES TARGET PRICE TO $60 FROM $39
Reuters · 04/10 03:47
Weekly Report: what happened at VERA last week (0401-0405)?
Weekly Report · 04/08 12:11
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
Ars Pharmaceuticals increased its stake in the biopharmaceutical company to 10,860,977 shares. Bain Capital Investors reduced its stake of the company to 2,697,267 shares. Vera Therapeutics and Takeda Pharmaceutical cut their stakes in the pharmaceutical company.
Barron‘s · 04/05 22:30
Commit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Options
NASDAQ · 04/05 15:36
More
Webull provides a variety of real-time VERA stock news. You can receive the latest news about Vera Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.